ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate after failing to show a favorable benefit-risk profile in a phase 1b trial.

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in inflammation.

Biopharma Trevena has whittled its team down to four people, saying goodbye to several C-suite execs and continuing a strategic review that includes possible asset sale, merger or closure of the company.

Viracta Therapeutics is implementing its second round of layoffs in just three months as the cash-strapped biotech tries to keep funds flowing to its lymphoma program.

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception.

A team of researchers led by Stanford University and San Diego-based Boundless Bio have identified an oral small molecule that specifically targets extrachromosomal DNA in cancer cells, preventing the DNA from repairing itself. When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to another cancer drug.

Among Novo’s semaglutide-based drugs, diabetes blockbuster Ozempic fell short of analysts' expectations during the third quarter while weight-loss med Wegovy came above a consensus estimate.